The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 22, 2007
Filed:
Dec. 05, 2003
Prasad V. Chaturvedula, Cheshire, CT (US);
Ling Chen, Middletown, CT (US);
Rita Civiello, Killingworth, CT (US);
Andrew P. Degnan, New Haven, CT (US);
Gene M. Dubowchik, Middlefield, CT (US);
Xiaojun Han, Cheshire, CT (US);
Xiang Jun J. Jiang, Hamden, CT (US);
George N. Karageorge, Portland, CT (US);
Guanglin Luo, Madison, CT (US);
John E. Macor, Guilford, CT (US);
Graham Poindexter, Old Saybrook, CT (US);
George Tora, Meriden, CT (US);
Prasad V. Chaturvedula, Cheshire, CT (US);
Ling Chen, Middletown, CT (US);
Rita Civiello, Killingworth, CT (US);
Andrew P. Degnan, New Haven, CT (US);
Gene M. Dubowchik, Middlefield, CT (US);
Xiaojun Han, Cheshire, CT (US);
Xiang Jun J. Jiang, Hamden, CT (US);
George N. Karageorge, Portland, CT (US);
Guanglin Luo, Madison, CT (US);
John E. Macor, Guilford, CT (US);
Graham Poindexter, Old Saybrook, CT (US);
George Tora, Meriden, CT (US);
Bristol-Myers Squibb Company, Princeton, NJ (US);
Abstract
The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors ('CGRP-receptor'), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.